EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

CHD1, a multifaceted epigenetic remodeler in prostate cancer

Haoyan Li, Loraine Gigi, Di Zhao

Frontiers in Oncology · 26.01.2023 · 13

DOI: 10.3389/fonc.2023.1123362 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Frontiers in Oncology, online erschienen am 26.01.2023. Verfasst von Haoyan Li und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 148 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, Cancer Prevention and Research Institute of Texas, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chromatin remodeling proteins contribute to DNA replication, transcription, repair, and recombination. The chromodomain helicase DNA-binding (CHD) family of remodelers plays crucial roles in embryonic development, hematopoiesis, and neurogenesis. As the founding member, CHD1 is capable of assembling nucleosomes, remodeling chromatin structure, and regulating gene transcription. Dysregulation of CHD1 at genetic, epigenetic, and post-translational levels is common in malignancies and other human diseases. Through interacting with different genetic alterations, CHD1 possesses the capabilities to exert oncogenic or tumor-suppressive functions in context-dependent manners. In this Review, we summarize the biochemical properties and dysregulation of CHD1 in cancer cells, and then discuss CHD1’s roles in different contexts of prostate cancer, with an emphasis on its crosstalk with diverse signaling pathways. Furthermore, we highlight the potential therapeutic strategies for cancers with dysregulated CHD1. At last, we discuss current research gaps in understanding CHD1’s biological functions and molecular basis during disease progression, as well as the modeling systems for biology study and therapeutic development.

Schlagwörter

Stichwörter der Autor:innen

CHD1dysregulationepigenetic remodelerprostate cancertherapeutic strategy

Autor:innen und Institutionen

  • Department of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
  • Texas A&M School of Public Health, Texas A&M University, College Station, TX, United States.

Förderung

  • NCI NIH HHS
  • Cancer Prevention and Research Institute of Texas
  • National Institutes of Health
  • Prostate Cancer Foundation

Zitieren

APA

Li, H., Gigi, L., & Zhao, D. (2023). CHD1, a multifaceted epigenetic remodeler in prostate cancer. Frontiers in Oncology, 13. https://doi.org/10.3389/fonc.2023.1123362

Vancouver

Li H, Gigi L, Zhao D. CHD1, a multifaceted epigenetic remodeler in prostate cancer. Frontiers in Oncology. 2023;13. doi:10.3389/fonc.2023.1123362

BibTeX
@article{Li2023,
  author = {Li, Haoyan and Gigi, Loraine and Zhao, Di},
  title = {CHD1, a multifaceted epigenetic remodeler in prostate cancer},
  journal = {Frontiers in Oncology},
  year = {2023},
  volume = {13},
  doi = {10.3389/fonc.2023.1123362}
}
Kostenlos starten →